A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements; Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma; LBCL With IRF4 Rearrangement; High-grade B-cell Lymphoma With 11q Aberration; Epstein-Barr Virus-Positive DLBCL; DLBCL Associated With Chronic Inflammation; Fibrin-associated LBCL; Primary Cutaneous DLBCL, Leg Type; Intravascular LBCL; Primary Mediastinal LBCL; High-grade B-cell Lymphoma; DLBCL Arising From Transformed Indolent Lymphoma; Mediastinal Gray Zone Lymphoma; FL Grade 3B; MCL Interventions: Drug: ATA3219 Sponsors: Atara Biotherapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials